http://pharmadispatch.com/news/boost-for-biota-with-revised-merger-proposal-set-to-get-go-ahead 2012-09-17T19:35:16+10:00 http://pharmadispatch.com/news/pharmaxis-breaking-new-ground-for-australian-pharma 2012-09-26T19:36:03+10:00 http://pharmadispatch.com/news/is-the-pharmaceutical-industry-tired-of-being-lectured-by-its-cr 2012-09-17T22:12:32+10:00 http://pharmadispatch.com/news/big-bad-pharma-to-blame-again 2012-09-27T22:13:37+10:00 http://pharmadispatch.com/news/pbs-spending-slows-as-the-patent-cliff-and-price-disclosure-hit 2012-09-17T23:06:28+10:00 http://pharmadispatch.com/news/pre-payment-to-avoid-the-means-test-leads-to-blowout-in-cost-of- 2012-09-23T23:08:34+10:00 http://pharmadispatch.com/news/ama-calls-for-action-from-health-ministers 2012-09-25T23:08:47+10:00 http://pharmadispatch.com/news/anger-grows-over-health-fund-plans-for-dr-review-website 2012-09-25T23:09:35+10:00 http://pharmadispatch.com/news/transparency-call-as-industry-targets-pharmac 2012-09-25T23:10:22+10:00 http://pharmadispatch.com/news/companies-face-higher-fees-for-pbs-listing 2012-09-25T23:11:20+10:00 http://pharmadispatch.com/news/another-tough-year-ahead-for-wholesalers 2012-09-25T23:12:02+10:00 http://pharmadispatch.com/news/government-report-confirms-pbs-slowdown-but-concessional-patient 2012-09-25T23:12:46+10:00 http://pharmadispatch.com/news/better-outlook-for-global-and-local-pharma 2012-09-26T23:14:01+10:00 http://pharmadispatch.com/news/governments-fight-over-who-needs-to-fund-extra-training-places 2012-09-26T23:14:40+10:00 http://pharmadispatch.com/news/states-yet-to-accept-federal-governments-funding-100-extra-train 2012-09-27T23:15:26+10:00 http://pharmadispatch.com/news/it-executives-back-e-health-despite-slow-consumer-uptake 2012-09-27T23:16:38+10:00 http://pharmadispatch.com/news/dementia-on-the-rise-as-population-continues-to-age 2012-09-27T23:17:26+10:00 http://pharmadispatch.com/news/the-forecast-for-pbs-spending-has-fallen-dramatically-saving-the 2012-09-30T22:53:11+10:00 http://pharmadispatch.com/news/terry-white-pushes-retail-to-offset-pbs-cuts 2012-10-01T19:36:46+10:00 http://pharmadispatch.com/news/change-underway-at-az-as-new-ceo-suspends-share-buyback-what-wil 2012-10-02T19:37:45+10:00 http://pharmadispatch.com/news/amgen-on-the-rise-as-share-price-hits-all-time-high 2012-10-03T19:40:39+10:00 http://pharmadispatch.com/news/mayne-pharma-targets-us-generics-market-with-acquisition-of-metr 2012-10-04T19:47:02+10:00 http://pharmadispatch.com/news/hard-to-justify-a-new-round-of-pbs-savings 2012-09-30T22:14:34+10:00 http://pharmadispatch.com/news/its-now-a-grand-conspiracy-according-to-industry-critics 2012-10-02T22:15:24+10:00 http://pharmadispatch.com/news/trade-agreement-can-improve-nzs-pharmac 2012-09-27T23:18:11+10:00 http://pharmadispatch.com/news/pbs-hot-issues-revealed-in-ministerial-briefings 2012-09-27T23:18:56+10:00 http://pharmadispatch.com/news/3-billion-lost-from-pbs-forecasts-in-just-14-months 2012-09-30T23:20:54+10:00 http://pharmadispatch.com/news/new-savings-measures-for-pbs-on-the-cards-as-government-extends- 2012-09-30T23:21:05+10:00 http://pharmadispatch.com/news/ausbiotech-urges-caution-on-compulsory-licences 2012-10-01T23:25:24+10:00 http://pharmadispatch.com/news/industry-leaders-call-for-stronger-ip-protection-in-trade-agreem 2012-10-01T23:26:17+10:00 http://pharmadispatch.com/news/health-funds-continue-to-shun-prescription-medicines 2012-10-02T23:27:39+10:00 http://pharmadispatch.com/news/az-pulled-tga-submission-for-latest-nexium-combo 2012-10-02T23:33:04+10:00 http://pharmadispatch.com/news/medical-students-join-call-for-end-to-political-stalemate-on-int 2012-10-03T23:33:57+10:00 http://pharmadispatch.com/news/gardasil-given-the-green-light-from-us-safety-study 2012-10-03T23:34:53+10:00 http://pharmadispatch.com/news/experimental-merck-co-diabetes-drug-proves-effective-in-latest-t 2012-10-03T23:35:34+10:00 http://pharmadispatch.com/news/industry-welcomes-mckeon-review-of-health-and-medical-research 2012-10-03T23:36:31+10:00 http://pharmadispatch.com/news/pbac-announce-drug-utilisation-and-listing-review-for-type-2-dia 2012-10-04T23:37:29+10:00 http://pharmadispatch.com/news/pharmaceuticals-as-a-share-of-the-federal-health-budget-the-lowe 2012-10-10T23:15:48+11:00 http://pharmadispatch.com/news/32-pbs-savings-measures-announced-since-2002-03-7-of-the-last-11 2012-10-06T22:38:13+10:00 http://pharmadispatch.com/news/lilly-set-on-becoming-a-global-diabetes-powerhouse 2012-10-09T20:47:46+11:00 http://pharmadispatch.com/news/pharmaxis-moves-ahead-as-bronchitol-makes-progress-in-europe 2012-10-10T20:48:45+11:00 http://pharmadispatch.com/news/qrxpharma-licenses-leading-product-to-canadian-partner 2012-10-10T20:50:28+11:00 http://pharmadispatch.com/news/no-comment-from-pharmaxis-on-takeover-speculation 2012-10-10T21:20:42+11:00 http://pharmadispatch.com/news/a-second-mou-is-the-industrys-best-chance-to-influence-reform 2012-10-06T22:16:25+10:00 http://pharmadispatch.com/news/tga-announce-recall-of-batches-of-typhoid-vaccines 2012-10-04T23:38:33+10:00 http://pharmadispatch.com/news/health-department-recalls-anatomy-poster-over-errors 2012-10-06T23:40:02+10:00 http://pharmadispatch.com/news/new-pbs-savings-on-their-way-if-history-the-guide 2012-10-06T23:45:51+10:00 http://pharmadispatch.com/news/tga-seizes-counterfeit-medicines 2012-10-08T00:47:00+11:00 http://pharmadispatch.com/news/novartis-well-placed-to-manage-impact-of-patent-losses 2012-10-08T00:47:42+11:00 http://pharmadispatch.com/news/patients-win-as-cheap-generic-lipitor-floods-the-market 2012-10-09T00:48:52+11:00 http://pharmadispatch.com/news/industry-conferences-an-opportunity-for-pharma-and-biotech 2012-10-09T00:52:12+11:00 http://pharmadispatch.com/news/merck-backs-australian-vaccine-technology 2012-10-09T00:52:59+11:00 http://pharmadispatch.com/news/lilly-shares-jump-on-alzheimers-hope 2012-10-09T00:53:42+11:00 http://pharmadispatch.com/news/pharmaceuticals-share-of-health-health-budget-hits-lowest-level- 2012-10-10T00:54:27+11:00 http://pharmadispatch.com/news/new-pic-chair-highlights-industry-challenges 2012-10-10T00:55:57+11:00 http://pharmadispatch.com/news/az-takes-global-rights-for-ardelyx-renal-drug 2012-10-11T00:56:56+11:00 http://pharmadispatch.com/news/tga-confirm-decision-to-put-new-ibuprofen-combo-on-supermarket-s 2012-10-11T00:57:40+11:00 http://pharmadispatch.com/news/nusep-to-spinout-fast-growing-prime-biologics-business 2012-10-14T20:51:39+11:00 http://pharmadispatch.com/news/prime-biomeds-ovarian-cancer-treatment-finds-success-in-trials 2012-10-14T21:19:20+11:00 http://pharmadispatch.com/news/18-months-and-all-we-have-is-a-website-seriosuly 2012-10-11T23:17:29+11:00 http://pharmadispatch.com/news/no-real-choice-for-ma-as-savings-push-gathers-steam 2012-10-14T23:18:23+11:00 http://pharmadispatch.com/news/govt-sending-the-wrong-signal-on-pharmaceutical-patents 2012-10-14T23:19:14+11:00 http://pharmadispatch.com/news/tga-announce-recall-of-another-vaccine-batch 2012-10-11T00:58:35+11:00 http://pharmadispatch.com/news/byetta-boosts-local-diabetes-alliance 2012-10-12T00:59:20+11:00 http://pharmadispatch.com/news/biogens-bg-12-emerging-as-leading-challenger-for-oral-ms-market 2012-10-14T01:00:08+11:00 http://pharmadispatch.com/news/merck-and-amgen-to-square-off-in-battle-for-osteoporosis-market 2012-10-15T01:01:11+11:00 http://pharmadispatch.com/news/minister-to-find-savings-in-health-as-ma-agrees-to-meet 2012-10-15T01:02:22+11:00 http://pharmadispatch.com/news/pharmaceutical-patent-term-at-risk-as-government-reviews-5-year- 2012-10-15T01:03:16+11:00 http://pharmadispatch.com/news/new-class-action-against-jj 2012-10-16T01:04:11+11:00 http://pharmadispatch.com/news/ausbiotech-cautions-govt-on-patent-reviews 2012-10-16T01:04:50+11:00 http://pharmadispatch.com/news/govt-the-big-winner-as-drug-falls-below-co-pay 2012-10-16T01:05:31+11:00 http://pharmadispatch.com/news/chemist-warehouse-breached-advertising-rule-with-free-lipitor 2012-10-16T01:10:44+11:00 http://pharmadispatch.com/news/health-officials-face-senate-scrutiny-wednesday 2012-10-17T01:26:17+11:00 http://pharmadispatch.com/news/patents-critical-for-investors-in-biotechnology 2012-10-17T01:27:00+11:00 http://pharmadispatch.com/news/research-grants-facing-the-axe-in-mid-year-review 2012-10-17T01:27:42+11:00 http://pharmadispatch.com/news/five-australian-biotechs-in-the-spotlight-at-investor-conference 2012-10-17T01:28:33+11:00 http://pharmadispatch.com/news/partnerships-the-way-to-go-post-gfc-according-to-industry-leader 2012-10-18T01:29:19+11:00 http://pharmadispatch.com/news/positive-signs-for-viralytcs-melanoma-drug 2012-10-21T20:52:25+11:00 http://pharmadispatch.com/news/another-china-patent-win-for-benitecs-hepatitis-drug 2012-10-21T20:53:11+11:00 http://pharmadispatch.com/news/political-support-essential-to-ensure-the-future-of-australian-p 2012-10-21T23:20:24+11:00 http://pharmadispatch.com/news/short-term-risks-for-industry-as-pressure-builds-on-health 2012-10-21T23:21:30+11:00 http://pharmadispatch.com/news/nps-will-need-to-compete-for-its-200-million 2012-10-18T01:30:15+11:00 http://pharmadispatch.com/news/health-officials-confirm-savings-required-to-offset-new-listings 2012-10-18T01:30:59+11:00 http://pharmadispatch.com/news/govt-only-on-track-to-achieve-mou-savings 2012-10-18T01:31:47+11:00 http://pharmadispatch.com/news/pradaxa-decision-closer 2012-10-18T01:32:29+11:00 http://pharmadispatch.com/news/novartis-gilenya-achieved-fastest-ever-cabinet-approval 2012-10-18T01:33:06+11:00 http://pharmadispatch.com/news/setback-for-biota-merger 2012-10-18T01:33:51+11:00 http://pharmadispatch.com/news/melanoma-patients-still-waiting-on-pbac-and-hoping 2012-10-18T01:34:35+11:00 http://pharmadispatch.com/news/a-second-chance-for-anna 2012-10-19T01:35:27+11:00 http://pharmadispatch.com/news/govt-should-focus-on-commercialisation-initiatives 2012-10-19T01:36:09+11:00 http://pharmadispatch.com/news/increased-risk-of-cv-events-with-diclofenac 2012-10-22T01:36:55+11:00 http://pharmadispatch.com/news/liveris-calls-on-govt-to-encourage-biotech-and-advanced-manufact 2012-10-22T01:37:42+11:00 http://pharmadispatch.com/news/nhmrc-grants-announced-but-other-programs-remain-in-doubt 2012-10-22T01:38:30+11:00 http://pharmadispatch.com/news/focus-on-patient-need-the-best-way-forward-for-start-ups 2012-10-22T01:39:32+11:00 http://pharmadispatch.com/news/govt-mid-year-review-should-give-clearer-picture-on-pbs-spend 2012-10-22T01:40:16+11:00 http://pharmadispatch.com/news/az-disappointed-as-govt-banks-almost-1-billion-from-high-potency 2012-10-22T01:41:49+11:00 http://pharmadispatch.com/news/govt-cuts-forecast-health-spending-by-1-66-billion 2012-10-22T01:43:21+11:00 http://pharmadispatch.com/news/hello-world-2 2012-10-24T13:54:09+11:00 http://pharmadispatch.com/news/sirtex-aiming-to-become-global-leader 2012-10-22T20:54:12+11:00 http://pharmadispatch.com/news/melbourne-based-avexa-in-partnership-discussions-for-its-lead-co 2012-10-22T20:55:21+11:00 http://pharmadispatch.com/news/biota-merger-gets-go-ahead 2012-10-23T20:55:40+11:00 http://pharmadispatch.com/news/amgen-posts-another-strong-result-on-the-back-of-us-sales 2012-10-23T20:56:35+11:00 http://pharmadispatch.com/news/strong-results-for-gilead-as-it-progresses-hep-c-therapy 2012-10-23T20:57:45+11:00 http://pharmadispatch.com/news/lilly-looks-to-its-pipeline-as-zyprexa-generics-hit-sales 2012-10-24T20:58:59+11:00 http://pharmadispatch.com/news/generics-hit-as-bms-looks-to-the-future 2012-10-23T21:01:08+11:00 http://pharmadispatch.com/news/astrazeneca-and-sanofi-hit-global-patent-clff 2012-10-25T21:04:20+11:00 http://pharmadispatch.com/news/govt-takes-500-million-from-research 2012-10-22T02:16:50+11:00 http://pharmadispatch.com/news/cabinet-to-get-tougher-as-the-queue-gets-longer 2012-10-24T02:18:37+11:00 http://pharmadispatch.com/news/industry-gets-caught-as-bad-forecasts-and-under-spending-frame-p 2012-10-24T02:20:01+11:00 http://pharmadispatch.com/news/a-major-victory-for-bayers-eylea 2012-10-24T02:26:56+11:00 http://pharmadispatch.com/news/minister-announces-listings-and-price-increases 2012-10-24T02:27:49+11:00 http://pharmadispatch.com/news/pat-clear-awards-for-pfizers-mendel-grobler 2012-10-24T02:28:45+11:00 http://pharmadispatch.com/news/job-cuts-hit-industry-giant-as-patent-expiry-bites 2012-10-25T02:29:29+11:00 http://pharmadispatch.com/news/api-grows-retail-and-cuts-discounts-to-manage-pbs-reforms 2012-10-25T02:30:25+11:00 http://pharmadispatch.com/news/another-12-months-before-under-co-pay-data-made-public 2012-10-26T02:31:22+11:00 http://pharmadispatch.com/news/payments-to-individual-doctors-on-the-agenda-as-accc-issues-draf 2012-10-27T02:32:01+11:00 http://pharmadispatch.com/news/pradaxa-review-a-stalling-tactic 2012-10-27T02:32:53+11:00 http://pharmadispatch.com/news/pfizer-revenue-falls-on-lipitor-patent-loss 2012-11-02T03:54:25+11:00 http://pharmadispatch.com/news/ma-guessed-right-with-transparency-working-group 2012-10-27T23:22:31+11:00 http://pharmadispatch.com/news/unworkable-sunshine-act-must-be-avoided 2012-10-30T23:23:20+11:00 http://pharmadispatch.com/news/as-one-china-boom-ends-another-begins 2012-10-27T02:33:35+11:00 http://pharmadispatch.com/news/disclosure-of-doctor-payments-coming-as-accc-targets-patient-pro 2012-10-28T02:34:25+11:00 http://pharmadispatch.com/news/nps-to-announce-record-pbs-savings 2012-10-28T02:35:21+11:00 http://pharmadispatch.com/news/impact-of-patent-losses-dominate-announcements 2012-10-28T02:36:06+11:00 http://pharmadispatch.com/news/boost-for-pharmaxis-as-uk-nice-approves-bronchitol 2012-10-29T02:36:55+11:00 http://pharmadispatch.com/news/merger-delivers-for-biota-staff 2012-10-29T02:37:47+11:00 http://pharmadispatch.com/news/guild-mourns-former-leader 2012-10-29T02:38:53+11:00 http://pharmadispatch.com/news/budget-pressure-adds-up-to-clever-accounting-for-nps-medicinewis 2012-10-30T02:39:27+11:00 http://pharmadispatch.com/news/pfizer-reschedules-results-announcement 2012-10-31T02:43:08+11:00 http://pharmadispatch.com/news/strong-results-as-bayer-boosts-its-consumer-division 2012-10-31T02:44:05+11:00 http://pharmadispatch.com/news/consumer-group-calls-for-incentives 2012-10-31T02:44:53+11:00 http://pharmadispatch.com/news/psa-signs-mou-with-japanese-counterpart 2012-11-01T02:46:14+11:00 http://pharmadispatch.com/news/nps-medicinewise-responds-to-questions 2012-11-01T02:46:58+11:00 http://pharmadispatch.com/news/e-health-initiatives-giving-consumers-the-power 2012-11-01T02:48:36+11:00 http://pharmadispatch.com/news/busy-day-for-maybe-pharma 2012-11-02T02:50:01+11:00 http://pharmadispatch.com/news/pfizer-revenue-falls-on-lipitor-patent-loss-2 2012-11-02T02:50:56+11:00 http://pharmadispatch.com/news/review-of-alzheimers-medicines-calls-for-tougher-continuation-ru 2012-11-04T02:51:44+11:00 http://pharmadispatch.com/news/second-mou-may-not-suit-government 2012-11-04T23:24:10+11:00 http://pharmadispatch.com/news/industry-enters-the-budget-danger-zone 2012-11-10T23:24:55+11:00 http://pharmadispatch.com/news/its-not-all-about-funding-according-to-us-expert 2012-11-04T02:53:02+11:00 http://pharmadispatch.com/news/ausbiotech-signals-closer-relationship-with-ma-with-board-electi 2012-11-04T02:53:43+11:00 http://pharmadispatch.com/news/department-of-innovation-slams-tga-review 2012-11-05T02:54:34+11:00 http://pharmadispatch.com/news/a-bonanza-for-government-that-could-be-coming-to-an-end 2012-11-05T02:55:11+11:00 http://pharmadispatch.com/news/710 2012-11-07T03:18:09+11:00 http://pharmadispatch.com/news/new-cholesterol-treatments-share-the-stage-at-aha 2012-11-07T03:20:50+11:00 http://pharmadispatch.com/news/staff-costs-drive-12-million-jump-in-tga-fees 2012-11-08T03:21:44+11:00 http://pharmadispatch.com/news/ausbiotech-declares-conference-a-success 2012-11-08T03:24:42+11:00 http://pharmadispatch.com/news/cash-boost-for-biota-from-rd-tax-incentive 2012-11-08T03:25:31+11:00 http://pharmadispatch.com/news/novartis-promotes-a-pipeline-full-of-potential-blockbusters 2012-11-09T03:26:14+11:00 http://pharmadispatch.com/news/generic-lipitor-delivers-ranbaxy-a-short-term-boost 2012-11-11T03:27:07+11:00 http://pharmadispatch.com/news/a-bonanza-for-government-that-could-be-coming-to-an-end-part-3 2012-11-11T03:30:40+11:00 http://pharmadispatch.com/news/merck-co-progresses-hep-c-therapies 2012-11-11T03:33:38+11:00 http://pharmadispatch.com/news/gsk-to-continue-vaccine-development-despite-setback 2012-11-11T03:34:24+11:00 http://pharmadispatch.com/news/industry-critics-mobilise-in-advance-of-accc-conference 2012-11-12T03:35:08+11:00 http://pharmadispatch.com/news/australias-communists-are-the-latest-fringe-group-to-criticise-t 2012-11-12T03:37:10+11:00 http://pharmadispatch.com/news/uk-industry-takes-on-nhs-failure-to-invest-in-medicines 2012-11-12T03:38:08+11:00 http://pharmadispatch.com/news/general-pbs-patients-hit-as-co-payment-heads-towards-40-2 2012-11-11T04:03:41+11:00 http://pharmadispatch.com/news/general-pbs-patients-hit-as-co-payment-heads-towards-40 2012-11-15T15:03:22+11:00 http://pharmadispatch.com/news/pharma-not-considered-innovative-despite-massive-rd-spend 2012-11-13T16:12:01+11:00 http://pharmadispatch.com/news/ma-calls-for-incentives-to-promote-investment-in-antibiotic-rese 2012-11-16T04:18:41+11:00 http://pharmadispatch.com/news/government-expected-budget-discussions-in-return-for-extending-d 2012-11-19T12:24:27+11:00 http://pharmadispatch.com/news/cabinet-approves-pfizers-lyrica 2012-11-20T03:06:01+11:00 http://pharmadispatch.com/news/lyrica-delay-shows-that-the-mou-will-be-gamed 2012-11-20T03:07:32+11:00 http://pharmadispatch.com/news/industry-confronts-pbs-groundhog-day 2012-11-20T03:22:20+11:00 http://pharmadispatch.com/news/general-co-payment-volumes-yet-to-recover-from-increase-part-2 2012-11-20T04:12:34+11:00 http://pharmadispatch.com/news/industry-critic-goes-too-far 2012-11-12T23:25:40+11:00 http://pharmadispatch.com/news/cancer-medicines-are-expensive-so-what 2012-11-14T23:26:21+11:00 http://pharmadispatch.com/news/industry-confronts-pbs-groundhog-day-2 2012-11-16T23:27:02+11:00 http://pharmadispatch.com/news/latest-study-shows-no-increased-risk-of-cv-events-with-champix 2012-11-13T03:39:02+11:00 http://pharmadispatch.com/news/industry-support-for-call-to-remove-critic-from-transparency-wor 2012-11-13T03:39:48+11:00 http://pharmadispatch.com/news/pharma-not-recognised-as-innovative-despite-rd-spend 2012-11-14T03:40:54+11:00 http://pharmadispatch.com/news/pharmacy-the-big-winner-in-health-survey 2012-11-18T03:49:40+11:00 http://pharmadispatch.com/news/more-job-losses-but-wheres-the-outcry 2012-11-25T17:45:35+11:00 http://pharmadispatch.com/news/companies-face-extended-time-to-list-post-cabinet-approval 2012-11-25T17:40:03+11:00 http://pharmadispatch.com/news/govt-talks-tough-industry-maintains-opposition-to-new-measures 2012-11-25T17:42:01+11:00 http://pharmadispatch.com/news/high-stakes-in-chemo-pricing-debate 2012-11-25T17:33:35+11:00 http://pharmadispatch.com/news/pharma-industry-doing-well-when-it-come-to-access-initiatives 2012-11-20T18:27:10+11:00 http://pharmadispatch.com/news/welcome-to-pharmadispatch 2012-11-26T03:26:19+11:00 http://pharmadispatch.com/news/ranbaxy-australia-not-impacted-by-us-recall 2012-11-27T18:01:22+11:00 http://pharmadispatch.com/news/campaign-in-support-of-hep-c-medicines-as-cabinet-queue-grows 2012-11-27T18:08:46+11:00 http://pharmadispatch.com/news/more-industry-jobs-lost-with-gsk-restructure 2012-11-27T22:43:40+11:00 http://pharmadispatch.com/news/listing-times-for-high-cost-medicines-has-improved-under-the-mou 2012-11-28T18:48:00+11:00 http://pharmadispatch.com/news/canadian-study-highlights-warfarin-safety-risk 2012-11-28T18:09:00+11:00 http://pharmadispatch.com/news/novartis-declares-a-crisis-in-uk-pharmaceutical-rd 2012-11-28T18:11:13+11:00 http://pharmadispatch.com/news/csl-upgrades-profit-forecast 2012-11-28T18:22:10+11:00 http://pharmadispatch.com/news/gsk-tops-access-to-medicines-index-for-third-straight-time 2012-11-29T17:45:05+11:00 http://pharmadispatch.com/news/25-price-cut-for-atorvastatin-but-private-prescription-still-che 2012-11-29T17:42:02+11:00 http://pharmadispatch.com/news/nz-defends-pharmac-in-trade-negotiations-kind-of 2012-11-30T17:40:47+11:00 http://pharmadispatch.com/news/chemo-drug-pricing-reveals-much-wider-issue 2012-11-30T18:40:32+11:00 http://pharmadispatch.com/news/dr-dominic-barnes-leading-the-industry-through-a-minefield-to-gr 2012-12-03T18:30:00+11:00 http://pharmadispatch.com/news/consumers-should-hope-for-the-inclusion-of-pharmaceuticals-in-tr 2012-12-03T18:39:35+11:00 http://pharmadispatch.com/news/novartis-highlights-strength-of-oncology-pipeline 2012-12-03T18:26:14+11:00 http://pharmadispatch.com/news/progress-for-msd-insomnia-drug 2012-12-03T18:24:40+11:00 http://pharmadispatch.com/news/ranbaxy-halts-production-of-atorvastatin 2012-12-03T18:29:24+11:00 http://pharmadispatch.com/news/more-industry-critics-join-transparency-group 2012-12-03T18:51:18+11:00 http://pharmadispatch.com/news/ma-says-chemo-drug-issue-shows-why-now-is-not-the-time-for-more- 2012-12-03T18:53:06+11:00 http://pharmadispatch.com/news/tga-updates-gilenya-pi 2012-12-04T17:54:26+11:00 http://pharmadispatch.com/news/gmia-calls-on-govt-not-to-impose-new-pbs-cuts 2012-12-04T17:56:00+11:00 http://pharmadispatch.com/news/price-of-medicines-not-keeping-pace-with-inflation 2012-12-05T18:29:46+11:00 http://pharmadispatch.com/news/merck-speculates-on-new-alzheimers-treatment 2012-12-05T18:28:32+11:00 http://pharmadispatch.com/news/a-united-front-from-industry-but-what-is-the-chf-doing 2012-12-05T18:31:17+11:00 http://pharmadispatch.com/news/az-reports-survival-analysis-from-faslodex-study 2012-12-07T18:09:45+11:00 http://pharmadispatch.com/news/chf-budget-submission-acknowledges-discussions-but-silent-on-the 2012-12-06T18:53:47+11:00 http://pharmadispatch.com/news/ma-chair-outlines-a-vision-for-australian-industry 2012-12-06T19:00:23+11:00 http://pharmadispatch.com/news/ma-chair-restates-industry-opposition-to-new-savings 2012-12-06T19:02:18+11:00 http://pharmadispatch.com/news/pharmacy-joins-opposition-to-new-pbs-budget-cuts 2012-12-07T18:12:53+11:00 http://pharmadispatch.com/news/cost-of-developing-new-medicines-continues-to-rise 2012-12-07T18:11:43+11:00 http://pharmadispatch.com/news/trade-pact-an-opportunity-for-industry-to-expose-critics 2012-12-10T19:08:15+11:00 http://pharmadispatch.com/news/cost-of-developing-a-new-medicine-continues-to-rise 2012-12-09T21:55:02+11:00 http://pharmadispatch.com/news/is-the-chf-conflicted-in-budget-discussions 2012-12-10T19:07:56+11:00 http://pharmadispatch.com/news/new-report-confirms-that-medicines-cut-health-costs 2012-12-10T19:06:47+11:00 http://pharmadispatch.com/news/competition-for-anti-coagulation-market-heats-up-but-all-eyes-re 2012-12-10T19:08:34+11:00 http://pharmadispatch.com/news/analysts-disagree-on-novartis 2012-12-10T19:06:27+11:00 http://pharmadispatch.com/news/csl-invests-in-local-manufacturing 2012-12-10T19:07:32+11:00 http://pharmadispatch.com/news/73-medicines-and-vaccines-in-development-to-treat-hiv 2012-12-10T19:07:11+11:00 http://pharmadispatch.com/news/implications-of-a-growing-private-market 2012-12-11T18:45:57+11:00 http://pharmadispatch.com/news/pradaxa-achieved-better-patient-outcomes-after-a-major-bleeding- 2012-12-11T18:34:52+11:00 http://pharmadispatch.com/news/private-market-competing-with-and-beating-the-pbs 2012-12-12T19:16:48+11:00 http://pharmadispatch.com/news/diagnosis-early-detection-and-treatments-improving-cancer-outcom 2012-12-12T19:08:44+11:00 http://pharmadispatch.com/news/ama-loses-its-secretary-general 2012-12-13T18:21:34+11:00 http://pharmadispatch.com/news/is-the-solution-two-markets-administered-separately 2012-12-13T18:31:09+11:00 http://pharmadispatch.com/news/progress-on-trade-pact-as-us-works-on-pharmac 2012-12-13T18:23:41+11:00 http://pharmadispatch.com/news/pradaxa-announcement-imminent 2012-12-14T18:31:45+11:00 http://pharmadispatch.com/news/annual-mapbac-meeting-constructive-and-useful 2012-12-14T18:30:17+11:00 http://pharmadispatch.com/news/new-ama-guidance-on-industry-relationships-but-nothing-on-transp 2012-12-14T18:29:04+11:00 http://pharmadispatch.com/news/another-patient-delay-as-pradaxa-heads-back-to-the-pbac 2012-12-19T00:59:06+11:00 http://pharmadispatch.com/news/gmia-remains-vigilant-of-new-budget-cuts 2012-12-17T18:43:38+11:00 http://pharmadispatch.com/news/nps-goes-into-data-collection 2012-12-17T18:39:03+11:00 http://pharmadispatch.com/news/new-service-takes-gp-consultation-online 2012-12-17T18:33:51+11:00 http://pharmadispatch.com/news/time-to-expose-double-standards 2012-12-17T19:08:01+11:00 http://pharmadispatch.com/news/australians-using-google-for-health-information 2012-12-18T16:32:53+11:00 http://pharmadispatch.com/news/has-regulation-fallen-behind-the-online-revolution 2012-12-18T16:36:13+11:00 http://pharmadispatch.com/news/ma-pradaxa-decision-a-bureaucratic-merry-go-round-and-debacle 2012-12-19T01:25:04+11:00 http://pharmadispatch.com/news/bi-deserves-better-than-what-it-got-yesterday 2012-12-19T15:32:32+11:00 http://pharmadispatch.com/news/review-was-all-about-price 2012-12-19T15:34:48+11:00 http://pharmadispatch.com/news/amgen-to-pay-us762-million-in-settlement-and-fines 2012-12-20T17:53:51+11:00 http://pharmadispatch.com/news/pfizer-to-reduce-us-sales-force 2012-12-20T17:41:23+11:00 http://pharmadispatch.com/news/doha-confirms-its-participation-in-tpp-discussions 2012-12-20T17:56:12+11:00 http://pharmadispatch.com/news/accc-rebuffs-industry-critics-in-code-authorisation 2012-12-21T01:19:17+11:00 http://pharmadispatch.com/news/time-to-look-beyond-the-next-two-years 2012-12-21T18:16:15+11:00